Silvia Damian

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 18

Top Topics

Tyrosine Kinase

Drug Administration

Top Venues

Nature medicine

JCO precision oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jacopo Azzollini, Iolanda Capone, Matteo Duca, Andrea Vingiani, Alberta Piccolo, Luca Agnelli, Elena Tamborini, Federica Perrone, Bernard Peissel, Daniele Lorenzini, Silvia Damian, Claudio Vernieri, Giulia Valeria Bianchi, Mara Mantiero, Monika Ducceschi, Maggie Polignano, Monica Niger, Federico Nichetti, Claudia Proto, Marta Brambilla, Elena Colombo, Marco Stellato, Elena Conca, Adele Busico, Siranoush Manoukian
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers? Tumori (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O'Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials. Tumori (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Andrea Vingiani, Luca Agnelli, Matteo Duca, Daniele Lorenzini, Silvia Damian, Claudia Proto, Monica Niger, Federico Nichetti, Elena Tamborini, Federica Perrone, Alberta Piccolo, Siranoush Manoukian, Jacopo Azzollini, Marta Brambilla, Elena Colombo, Salvatore Lopez, Claudio Vernieri, Francesca Marra, Elena Conca, Adele Busico, Iolanda Capone, Fabio Bozzi, Marta Angelini, Andrea Devecchi, Rebecca Salvatori, Valentina De Micheli, Anna Baggi, Silvia Pasini, Claudio Jommi, Vito Ladisa, Giovanni Apolone, Filippo De Braud, Giancarlo Pruneri
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. JCO precision oncology 7 (2023)
Iolanda Capone, Fabio Bozzi, Gian Paolo Dagrada, Paolo Verderio, Elena Conca, Adele Busico, Maria Adele Testi, Valentina Monti, Matteo Duca, Claudia Proto, Silvia Damian, Alberta Piccolo, Federica Perrone, Elena Tamborini, Andrea Devecchi, Paola Collini, Daniele Lorenzini, Andrea Vingiani, Luca Agnelli, Giancarlo Pruneri
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples. Exploration of targeted anti-tumor therapy 3 (5) (2022)
Robin Kate Kelley, Bruno Sangro, William Harris, Masafumi Ikeda, Takuji Okusaka, Yoon-Koo Kang, Shu-Kui Qin, David Wai-Meng Tai, Ho Yeong Lim, Thomas Yau, Wei Peng Yong, Ann-Lii Cheng, Antonio Gasbarrini, Silvia Damian, Jordi Bruix, Mitesh J Borad, Johanna Bendell, Tae-You Kim, Nathan Standifer, Philip He, Mallory Makowsky, Alejandra Negro, Masatoshi Kudo, Ghassan K Abou-Alfa
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (27) (2021)
Alessio Malacrida, Roberta Rigolio, Luigi Celio, Silvia Damian, Guido Cavaletti, Vincenzo Mazzaferro, Mariarosaria Miloso
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells. International journal of molecular sciences 22 (15) (2021)